ABSTRACT
Background This pragmatic randomized controlled trial aimed to assess the effect of a passive display of artificial intelligence (AI)-based predictive analytics on hours free of clinical deterioration events among medical and surgical patients in an acute care cardiology medical-surgical ward.
Methods 10,422 inpatient visits were randomly assigned by cluster to the intervention group of a display of risk trajectories or to a control group of usual medical care. The trial was undertaken on an 85-bed inpatient cardiology and cardiac surgery ward of an academic hospital with a substantial implementation and education plan. This was a passive display with no specific response mandated. The primary analysis compared events of clinical deterioration (death, emergent ICU transfer, emergent endotracheal intubation, cardiac arrest, or emergent surgery) and compared mortality 21 days after admission.
Results Patients with a large spike in risk score had, on average, twice the length of hospital stay (6.8 compared to 3.4 days). There was no change in the primary outcome between groups. Among those who had a clinical event, there were more event-free hours in the intervention/display-on group compared to the standard-of-care/display-off, but this did not approach statistical significance. 11% of patients were transferred into or out of display beds, a censoring event removing them from the analysis, thereby undermining aspects of the randomized nature of the study.
Conclusion Predictive analytics monitoring incorporating continuous cardiorespiratory monitoring and displays of risk trajectories coupled with an education plan did not improve patient outcomes or reduce deaths. While necessary to conduct the study, the pragmatic design allowed for significant movement towards intervention/displayed beds for sicker patients. Design considerations in the future must focus on understanding clinicians’ interpretation, care processes, and communication practices.
Trial registration NCT04359641
Competing Interest Statement
COI: MC is an employee of Nihon Kohden Digital Health Solutions. LPM and JRM are consultants for Nihon Kohden Digital Health Solutions. JKM owns equity shares of ArteraAI and JRM owns equity shares of Medical Predictive Science Corporation, whose products are not discussed in this unrelated work. The other authors do not express conflicts of interest.
Clinical Trial
NCT04359641
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/34043525/
Funding Statement
Funding: This study was funded by the Frederick Thomas Advanced Medical Analytics Fund, University of Virginia and AHRQ R01HS028803 (Keim-Malpass/Bourque MPI). The investigators received in-kind support from Nihon Kohden Digital Health Solutions for use and support of the CoMET system. The funders had no direct role/oversight of this published work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Instiutional Review Board of the Unviersity of Virginia gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This study was funded by the Frederick Thomas Advanced Medical Analytics Fund, University of Virginia and AHRQ R01HS028803 (Keim-Malpass/Bourque MPI). The investigators received in-kind support from Nihon Kohden Digital Health Solutions for use and support of the CoMET system. The funders had no direct role/oversight of this published work.
COI: MC is an employee of Nihon Kohden Digital Health Solutions. LPM and JRM are consultants for Nihon Kohden Digital Health Solutions. JKM owns equity shares of ArteraAI and JRM owns equity shares of Medical Predictive Science Corporation, whose products are not discussed in this unrelated work. The other authors do not express conflicts of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
